Hetronifly (Serplulimab)

Hetronifly (serplulimab) in combination with carboplatin and etoposide is used for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

Recommended Dosage:
The recommended dose of Serplulimab is 4.5 mg/kg administered every 3 weeks until disease progression or unacceptable toxicity. The initial infusion rate should be set up to 100 ml per hour. If the first infusion is well tolerated, all subsequent infusions may be shortened to 30 minutes (± 10 minutes). When administered along with chemotherapy, Serplulimab should be administered first, followed by chemotherapy on the same day. Use separate infusion bags for each infusion. Serplulimab must not be administered as an intravenous (IV) push or bolus injection.

• Immune-related side effects can affect multiple organs, including the skin, lungs, liver, kidneys, and endocrine glands. Monitor patients for signs and symptoms such as rash, diarrhea, cough, or abnormal liver tests. Promptly evaluate and treat suspected immune-related events quickly to avoid serious or life-threatening issues without delay.
• Immune-related colitis may occur as serious diarrhea, abdominal pain, or blood in the stool. For moderate to severe symptoms, stop serplulimab 100 mg/10 ml injection treatment. Start corticosteroids immediately and taper based on response. Treatment can be resumed cautiously only after colitis is resolved to grade ≤1. Always monitor for possible recurrence.
• Immune-related pituitary disorders such as hypophysitis may cause headache, fatigue, hormonal deficiencies, and vision changes. Check pituitary hormones and MRI imaging before and after starting serplulimab treatment. These disorders are best treated with high-dose corticoids and hormone replacement therapy. Long-term follow-up with endocrinology for monitoring recovery and persistently altered pituitary function is needed.
• Adrenal insufficiency may exist with nausea, fatigue, hypotension, and electrolyte disturbances from decreased cortisol levels. Monitor adrenal function and clinical signs throughout the treatment. Start prompt corticosteroid replacement when required. Educate patients on stress-dose steroids during illness or surgery. Consult endocrinology for comprehensive supportive care.
• Hyperglycaemia may occur from immune-mediated endocrine dysfunction. This may cause new or worsened diabetes. Monitor blood glucose levels at baseline and regularly throughout serplulimab therapy. Manage promptly with insulin or oral hypoglycaemics following standard guidelines. Educate patients to recognise hyperglycaemia symptoms and seek prompt medical advice early.
• Infusion-related reactions like fever, chills, rash, or hypotension can occur during or shortly after serplulimab infusion. Monitor patients continuously during infusion and for at least one hour afterwards. If reactions occur, interrupt or slow the infusion and administer supportive care. Consider pre-medication in high-risk individuals.
• Obtain negative pregnancy tests prior to therapy as pregnancy is contraindicated. Women of childbearing potential should be advised to not get pregnant during treatment and for three months post treatment. Report exposures to the registry.
• Serplulimab can harm a nursing child as it can be excreted in breast milk. Advise mothers not to breastfeed during treatment and for three months post-infusion. Infants exposed should be monitored for reactions while being referred to formula or donor milk until drug clearance is confirmed.
• Patients may experience dizziness, fatigue, or visual disturbances, which may impair driving and the operation of machines. Until patients fully understand their response, these activities should not be undertaken. In case such symptoms arise, therapy should be adjusted, and proper precautionary guidance provided to ensure safety.

What documents are required to import HETRONIFLY to India?

HETRONIFLY (serplulimab) injections can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is HETRONIFLY available in India?

HETRONIFLY (serplulimab injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Hetronifly in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

HETRONIFLY can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of HETRONIFLY (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Hetronifly 100 mg/10 ml injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source HETRONIFLY (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Hetronifly®?

Serplulimab is the Generic Name for the trade name drug Hetronifly®.

What is the Manufacturer's Name of Hetronifly®?

Hetronifly® is manufactured by Shanghai Henlius Biotech.

Is Hetronifly® approved by the FDA?

Hetronifly® (serplulimab) received EMA approval in May 2025 and China NMPA approval in June 2025. As of July 2025, it has not yet been approved by the U.S. FDA and remains subject to ongoing regulatory review and clinical safety evaluation.

What is the dosage and form of Hetronifly® supplied?

Hetronifly is supplied in Injections: 100 mg/10 ml of Serplulimab for intravenous (IV) administration.

What are the most common side effects of Hetronifly® 100 mg/10 ml Injection?

The most common side effects of Hetronifly® are fatigue, diarrhea, decreased appetite, rash, cough, and nausea. Some patients may also experience infusion-related reactions such as chills or fever.

How much does Hetronifly® 100 mg/10 ml Injection cost in India?

Hetronifly® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Prices of Hetronifly Injections may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Hetronifly 100 mg/10 ml cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Hetronifly® 100 mg/10 ml Injections be available in SAARC countries?

Apart from Gulf countries, Hetronifly® can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Hetronifly® Injections in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Hetronifly® 100 mg/10 ml Injections online in India?

Yes, one can buy Hetronifly 100 mg/10 ml online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Hetronifly® Injection through legal channels.

What are the storage conditions of Hetronifly® 100 mg/10 ml Injections?

Store in a refrigerator (2°C to 8°C). Do not freeze the medicine. Store in the original package to protect from the light.